OUR OFFER
QUICK AND ACCURATE DIAGNOSIS IS THE BASIS FOR EFFECTIVE TREATMENT
WE DEVELOP MODERN MEDICAL DIAGNOSTICS TO PROTECT HEALTH AND LIFE
The innovative products devised and developed by Scope Fluidics are a response to the immediate needs of the healthcare system, where fast and reliable diagnostics allows for accurate diagnosis, and thus effective treatment, of bacterial and viral infections.
Together with medical staff, we define real problems
and propose solutions based on the possibilities offered by advanced technologies.
Our systems represent a real change that contributes to improving the quality of health and protection of patients’ lives. It is also a way to reduce the length of treatment and minimize its costs.
OUR PRODUCTS
THE ANSWER TO ONE OF THE GREATEST CHALLENGES OF MODERN MEDICINE
The increasing resistance of microorganisms to drugs is one of the most serious threats to global health. Scope Fluidics responds to this challenge with an innovative system which makes it possible to gain full knowledge of resistance mechanisms and the sensitivity of bacteria to all available antibiotics.
The results of this work make it possible to implement effective therapy in patients, reduce complications after infections and reduce treatment and hospitalisation costs.
BACTEROMIC takes antibiotic susceptibility testing (AST) to the next level by offering quantitative assessment of all clinically relevant antibiotics and identification of synergistic antibiotic pairs.
The first fully automated system designed to test all relevant antibiotics in a single assay and to test combinations of antibiotics!
BACTEROMIC addresses the needs of such institutions as:
HOSPITALS
LABORATORIES
In 2024, two companies, EDOCERA and Hybolic, were established as part of the venture studio activity (Scope Discovery).
EDOCERA Company develops an innovative system for stroke prevention and real-time diagnosis. It combines a hardware device with AI-powered software to continuously monitor patient parameters. Using advanced algorithms, the system aims to detect critical signal changes that indicate a risk of stroke and immediately alert about the incident.
By significantly reducing the reaction time when a stroke occurs, the system will enable faster medical intervention, helping to minimize its negative consequences. The solution is going to enhance patient safety and give a sense of security to both individuals at risk and their families.
Hybolic Company develops an innovative system for the early detection of diabetes risk and metabolic disorders. Our goal is to combine a biomarker monitoring device with intelligent software that analyzes the concentration of key molecules such as glucose and insulin.
By leveraging advanced algorithms, we aim to identify early signals of insulin resistance years before the onset of the disease. Hybolic Company with its solution will support preventive healthcare and empower users to take control of their metabolic health.
